Uric acid transport and disease.

Uric acid is the metabolic end product of purine metabolism in humans. It has antioxidant properties that may be protective but can also be pro-oxidant, depending on its chemical microenvironment. Hyperuricemia predisposes to disease through the formation of urate crystals that cause gout, but hyperuricemia, independent of crystal formation, has also been linked with hypertension, atherosclerosis, insulin resistance, and diabetes. We discuss here the biology of urate metabolism and its role in disease. We also cover the genetics of urate transport, including URAT1, and recent studies identifying SLC2A9, which encodes the glucose transporter family isoform Glut9, as a major determinant of plasma uric acid levels and of gout development.

[1]  Yoshikatsu Kanai,et al.  The Multivalent PDZ Domain-containing Protein PDZK1 Regulates Transport Activity of Renal Urate-Anion Exchanger URAT1 via Its C Terminus* , 2004, Journal of Biological Chemistry.

[2]  William A. Richardson,et al.  SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout , 2008, Nature Genetics.

[3]  L. Kuller,et al.  Long-term cardiovascular mortality among middle-aged men with gout. , 2008, Archives of internal medicine.

[4]  A. Hofman,et al.  Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study , 2008, The Lancet.

[5]  J. Moley,et al.  Identification and Characterization of Human Glucose Transporter-like Protein-9 (GLUT9) , 2004, Journal of Biological Chemistry.

[6]  F. Russel,et al.  The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. , 2008, Kidney international.

[7]  Xin He,et al.  Modulation of renal apical organic anion transporter 4 function by two PDZ domain-containing proteins. , 2005, Journal of the American Society of Nephrology : JASN.

[8]  H. Endou,et al.  Immunolocalization of multispecific organic anion transporters, OAT1, OAT2, and OAT3, in rat kidney. , 2002, Journal of the American Society of Nephrology : JASN.

[9]  Y. Tavil,et al.  Uric acid level and its association with carotid intima-media thickness in patients with hypertension. , 2008, Atherosclerosis.

[10]  A. Enomoto,et al.  Function and localization of urate transporter 1 in mouse kidney. , 2004, Journal of the American Society of Nephrology : JASN.

[11]  E. Block,et al.  Hyperuricemia induces endothelial dysfunction. , 2005, Kidney international.

[12]  Y. Kanai,et al.  Human organic anion transporter 4 is a renal apical organic anion/dicarboxylate exchanger in the proximal tubules. , 2004, Journal of pharmacological sciences.

[13]  Ping Li,et al.  Uric Acid Stimulates Monocyte Chemoattractant Protein‐1 Production in Vascular Smooth Muscle Cells Via Mitogen‐Activated Protein Kinase and Cyclooxygenase‐2 , 2003, Hypertension.

[14]  R. Wortmann,et al.  Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. , 2004, The Journal of rheumatology.

[15]  F. Russel,et al.  Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4 , 2008, British journal of pharmacology.

[16]  Tsutomu Takahashi,et al.  Recurrent URAT1 gene mutations and prevalence of renal hypouricemia in Japanese , 2005, Pediatric Nephrology.

[17]  A. Angerhofer,et al.  Inactivation of Nitric Oxide by Uric Acid , 2008, Nucleosides, nucleotides & nucleic acids.

[18]  Y. Kanai,et al.  New insights into renal transport of urate , 2007, Current opinion in rheumatology.

[19]  T. Nakagawa,et al.  Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease. , 2005, Seminars in nephrology.

[20]  B. Ames,et al.  Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[21]  R. Glynn,et al.  Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. , 1987, The American journal of medicine.

[22]  W. Rathmann,et al.  Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults. , 1998, Annals of epidemiology.

[23]  W. R. Wikoff,et al.  Multiple organic anion transporters contribute to net renal excretion of uric acid. , 2008, Physiological genomics.

[24]  G. Reaven,et al.  Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. , 1991, JAMA.

[25]  C. Cheeseman,et al.  Mouse glucose transporter 9 splice variants are expressed in adult liver and kidney and are up-regulated in diabetes. , 2006, Molecular endocrinology.

[26]  G. Hotamisligil,et al.  Inflammation and metabolic disorders , 2006, Nature.

[27]  Daniel Levy,et al.  Serum Uric Acid and Risk for Cardiovascular Disease and Death: The Framingham Heart Study , 1999, Annals of Internal Medicine.

[28]  E. Block,et al.  Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. , 2008, American journal of physiology. Cell physiology.

[29]  R. Terkeltaub,et al.  Serum Uric Acid Is Associated with Carotid Plaques: The National Heart, Lung, and Blood Institute Family Heart Study , 2008, The Journal of Rheumatology.

[30]  J. Tschopp,et al.  The inflammasome: a danger sensing complex triggering innate immunity. , 2007, Current opinion in immunology.

[31]  P. Simkin.  The Dalmatian defect: a hepatic endocrinopathy of urate transport. , 2005, Arthritis and rheumatism.

[32]  T. Miura,et al.  Inhibition by uric acid of free radicals that damage biological molecules. , 2003, Pharmacology & toxicology.

[33]  O. Augusto,et al.  Uric acid oxidation by peroxynitrite: multiple reactions, free radical formation, and amplification of lipid oxidation. , 1999, Archives of biochemistry and biophysics.

[34]  K. Kaneko,et al.  Oxidative imbalance in idiopathic renal hypouricemia , 2009, Pediatric Nephrology.

[35]  D. Kang,et al.  Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. , 2005, Seminars in nephrology.

[36]  A. So.  Developments in the scientific and clinical understanding of gout , 2008, Arthritis research & therapy.

[37]  Hyon K. Choi,et al.  Independent Impact of Gout on Mortality and Risk for Coronary Heart Disease , 2007, Circulation.

[38]  F. Martinon,et al.  Gout-associated uric acid crystals activate the NALP3 inflammasome , 2006, Nature.

[39]  D. Tsai,et al.  Association Between Serum Uric Acid Level and Components of the Metabolic Syndrome , 2006, Journal of the Chinese Medical Association : JCMA.

[40]  M. Perdiguero,et al.  Gout, diuretics and the kidney , 2006, Annals of the rheumatic diseases.

[41]  H. Joost,et al.  The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members , 2001, Molecular membrane biology.

[42]  E. Boerwinkle,et al.  Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout , 2009, Proceedings of the National Academy of Sciences.

[43]  I. Hisatome,et al.  Plasma Urate Level Is Directly Regulated by a Voltage-driven Urate Efflux Transporter URATv1 (SLC2A9) in Humans* , 2008, Journal of Biological Chemistry.

[44]  Duk-Hee Kang,et al.  Uric acid and cardiovascular risk. , 2008, The New England journal of medicine.

[45]  Richard J. Johnson,et al.  Hyperuricemia in Childhood Primary Hypertension , 2003, Hypertension.

[46]  Mario Falchi,et al.  Genome-wide Association Study Identifies Genes for Biomarkers of Cardiovascular Disease: Serum Urate and Dyslipidemia , 2022 .

[47]  Y. Kanai,et al.  Cloning and Characterization of a Novel Multispecific Organic Anion Transporter * , 1997 .

[48]  Richard J. Johnson,et al.  Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. , 2008, JAMA.

[49]  K. Takata,et al.  Identification of a New Member of Type I Na/Phosphate Co-Transporter in the Rat Kidney , 2003, Nephron Physiology.

[50]  F. Kronenberg,et al.  Sex-Specific Association of the Putative Fructose Transporter SLC2A9 Variants With Uric Acid Levels Is Modified by BMI , 2008, Diabetes Care.

[51]  G. Burckhardt,et al.  Identification of a New Urate and High Affinity Nicotinate Transporter, hOAT10 (SLC22A13)* , 2008, Journal of Biological Chemistry.

[52]  I. Hisatome,et al.  Age and origin of the G774A mutation in SLC22A12 causing renal hypouricemia in Japanese , 2008, Clinical genetics.

[53]  P. Elliott,et al.  SLC2A9 Is a High-Capacity Urate Transporter in Humans , 2008, PLoS medicine.

[54]  P. Vollenweider,et al.  Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice. , 2003, Swiss medical weekly.

[55]  T. Svitkina,et al.  Mammalian CARMIL inhibits actin filament capping by capping protein. , 2005, Developmental cell.

[56]  Christian Gieger,et al.  Meta-Analysis of 28,141 Individuals Identifies Common Variants within Five New Loci That Influence Uric Acid Concentrations , 2009, PLoS genetics.

[57]  T. Nakagawa,et al.  Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. , 2007, American journal of physiology. Cell physiology.

[58]  N. Takahata,et al.  Loss of urate oxidase activity in hominoids and its evolutionary implications. , 2002, Molecular biology and evolution.

[59]  H. Kusuhara,et al.  Molecular Cloning and Characterization of a New Multispecific Organic Anion Transporter from Rat Brain* , 1999, The Journal of Biological Chemistry.

[60]  Hyon K. Choi,et al.  Hyperuricemia and risk of stroke: a systematic review and meta-analysis. , 2009, Arthritis and rheumatism.

[61]  P. Vollenweider,et al.  Partial gene deletion of endothelial nitric oxide synthase predisposes to exaggerated high-fat diet-induced insulin resistance and arterial hypertension. , 2004, Diabetes.

[62]  William A. Richardson,et al.  Homozygous SLC2A9 mutations cause severe renal hypouricemia. , 2010, Journal of the American Society of Nephrology : JASN.

[63]  J. Kim,et al.  Identification of a Novel Voltage-driven Organic Anion Transporter Present at Apical Membrane of Renal Proximal Tubule* , 2003, Journal of Biological Chemistry.

[64]  C. Cheeseman,et al.  A highly conserved hydrophobic motif in the exofacial vestibule of fructose transporting SLC2A proteins acts as a critical determinant of their substrate selectivity , 2007, Molecular membrane biology.

[65]  Y. Moriwaki,et al.  Close correlation between visceral fat accumulation and uric acid metabolism in healthy men. , 1997, Metabolism: clinical and experimental.

[66]  Nicola L. Beer,et al.  The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver , 2009, Human molecular genetics.

[67]  Y. Kanai,et al.  Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. , 2001, Molecular pharmacology.

[68]  K. Geering,et al.  Mouse GLUT9: evidences for a urate uniporter. , 2009, American journal of physiology. Renal physiology.

[69]  J. Erdmann,et al.  Common Polymorphisms Influencing Serum Uric Acid Levels Contribute to Susceptibility to Gout, but Not to Coronary Artery Disease , 2009, PloS one.

[70]  P. Vollenweider,et al.  Insulin Resistance, Hyperlipidemia, and Hypertension in Mice Lacking Endothelial Nitric Oxide Synthase , 2001, Circulation.

[71]  Roddy Edward,et al.  Gout , 2011 .

[72]  D. Felson,et al.  Drs. Neogi and Felson reply , 2009, The Journal of Rheumatology.

[73]  K. Saag,et al.  Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link? , 2009, Arthritis research & therapy.

[74]  D. Leake,et al.  Prooxidant and antioxidant properties of human serum ultrafiltrates toward LDL: important role of uric acid. , 2003, Journal of lipid research.

[75]  Hyon K. Choi,et al.  Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. , 2005, Archives of internal medicine.

[76]  K. Moley,et al.  GLUT9 is differentially expressed and targeted in the preimplantation embryo. , 2004, Endocrinology.

[77]  D. Harrison,et al.  Interactions of peroxynitrite with uric acid in the presence of ascorbate and thiols: implications for uncoupling endothelial nitric oxide synthase. , 2005, Biochemical pharmacology.

[78]  M. Lotz,et al.  Cytokine Regulation of Facilitated Glucose Transport in Human Articular Chondrocytes1 , 2001, The Journal of Immunology.

[79]  A. Mobasheri,et al.  Expression of the GLUT1 and GLUT9 facilitative glucose transporters in embryonic chondroblasts and mature chondrocytes in ovine articular cartilage , 2005, Cell biology international.

[80]  V. Cantisani,et al.  Serum uric acid and its association with metabolic syndrome and carotid atherosclerosis in obese children. , 2009, European journal of endocrinology.

[81]  J. H. Acosta,et al.  Essential hypertension, progressive renal disease, and uric acid: a pathogenetic link? , 2005, Journal of the American Society of Nephrology : JASN.

[82]  S. Bandinelli,et al.  The GLUT9 Gene Is Associated with Serum Uric Acid Levels in Sardinia and Chianti Cohorts , 2007, PLoS genetics.

[83]  K. Davies,et al.  Uric acid-iron ion complexes. A new aspect of the antioxidant functions of uric acid. , 1986, The Biochemical journal.

[84]  Toshinori Suzuki.  Nitrosation of uric acid induced by nitric oxide under aerobic conditions. , 2007, Nitric oxide : biology and chemistry.

[85]  J. Moley,et al.  Cloning and expression analysis of a novel member of the facilitative glucose transporter family, SLC2A9 (GLUT9). , 2000, Genomics.

[86]  C. Gieger,et al.  SLC2A9 influences uric acid concentrations with pronounced sex-specific effects , 2008, Nature Genetics.

[87]  B. Halliwell,et al.  A Reassessment of the Peroxynitrite Scavenging Activity of Uric Acid , 2002, Annals of the New York Academy of Sciences.

[88]  A. Garrod.  Observations on certain pathological conditions of the blood and urine, in gout, rheumatism, and Bright's disease. , 1848, Medico-chirurgical transactions.

[89]  Y. Kikuchi,et al.  Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. , 2008, American journal of human genetics.

[90]  J. Higaki,et al.  Elevated serum uric acid is an independent predictor for cardiovascular events in patients with severe coronary artery stenosis: subanalysis of the Japanese Coronary Artery Disease (JCAD) Study. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[91]  G. Burckhardt,et al.  Human renal organic anion transporter 4 operates as an asymmetric urate transporter. , 2007, Journal of the American Society of Nephrology : JASN.

[92]  A. Bradley,et al.  Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[93]  M. Gertler,et al.  Serum uric acid in relation to age and physique in health and in coronary heart disease. , 1951, Annals of internal medicine.

[94]  W. Bilker,et al.  Gout epidemiology: results from the UK General Practice Research Database, 1990–1999 , 2005, Annals of the rheumatic diseases.

[95]  G. Reaven.  Role of insulin resistance in human disease (syndrome X): an expanded definition. , 1993, Annual review of medicine.

[96]  Byung Jin Kim,et al.  Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. , 2005, Circulation journal : official journal of the Japanese Circulation Society.

[97]  F. Russel,et al.  Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. , 2005, American journal of physiology. Renal physiology.

[98]  Hirotaka Matsuo,et al.  Molecular identification of a renal urate–anion exchanger that regulates blood urate levels , 2002, Nature.

[99]  G. Burckhardt,et al.  Human Organic Anion Transporter 3 (hOAT3) can Operate as an Exchanger and Mediate Secretory Urate Flux , 2003, Cellular Physiology and Biochemistry.

[100]  G. Bellomo,et al.  When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: a study using uric acid. , 1999, The Biochemical journal.

[101]  R. Burcelin,et al.  Normal hepatic glucose production in the absence of GLUT2 reveals an alternative pathway for glucose release from hepatocytes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[102]  B. Thorens,et al.  Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy , 2009, Proceedings of the National Academy of Sciences.

[103]  M. Rieder,et al.  Common Missense Variant in the Glucokinase Regulatory Protein Gene Is Associated With Increased Plasma Triglyceride and C-Reactive Protein but Lower Fasting Glucose Concentrations , 2008, Diabetes.

[104]  J. Kim,et al.  Molecular Cloning and Characterization of Multispecific Organic Anion Transporter 4 Expressed in the Placenta* , 2000, The Journal of Biological Chemistry.

[105]  F. Russel,et al.  The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. , 2002, Journal of the American Society of Nephrology : JASN.

[106]  D. Bannasch,et al.  Mutations in the SLC2A9 Gene Cause Hyperuricosuria and Hyperuricemia in the Dog , 2008, PLoS genetics.